Heather A Bunting from Clarks Summit, PA, age 41

Medicine Doctors

Heather Bunting

view source

Specialties:

Family Medicine

Work:

Saint Marys Heartside Health Center
359 Division Ave S, Grand Rapids, MI 49503
616-685-3800 (phone), 616-235-0913 (fax)

Education:

Medical School
University of Michigan Medical School
Graduated: 2000

Procedures:

Arthrocentesis
Destruction of Benign/Premalignant Skin Lesions
Electrocardiogram (EKG or ECG)
Pulmonary Function Tests
Skin Tags Removal
Vaccine Administration

Conditions:

Abnormal Vaginal Bleeding
Alcohol Dependence
Anxiety Dissociative and Somatoform Disorders
Anxiety Phobic Disorders
Bipolar Disorder

Languages:

English
Spanish

Description:

Dr. Bunting graduated from the University of Michigan Medical School in 2000. She works in Grand Rapids, MI and specializes in Family Medicine. Dr. Bunting is affiliated with St Marys Of Michigan Medical Center.

Us Patents

Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
view source
US Patent:

20090069340, Mar 12, 2009
Filed:

Dec 22, 2005
Appl. No.:

11/793050
Inventors:

Michael Balestra - Wilmington DE, US
Heather Bunting - Wilmington DE, US
Deborah Chen - Biopolis Way, SG
Ian Egle - North York, CA
Janet Forst - Wilmington DE, US
Jennifer Frey - Brampton, CA
Methvin Isaac - Brampton, CA
Fupeng Ma - Brampton, CA
David Nugiel - Wilmington DE, US
Abdelmalik Slassi - Mississauga, CA
Gary Steelman - Wilmington DE, US
Guang-Ri Sun - Markham, CA
Babu Sundar - Wilmington DE, US
Radhakrishnan Ukkiramapandian - Salt Lake City UT, US
Rebecca Urbanek - Wilmington DE, US
Sally Walsh - Wilmington DE, US
Assignee:

AstraZeneca AB - Sodertalje
International Classification:

A61K 31/496
C07D 471/10
A61K 31/438
C07D 401/06
A61P 25/16
A61P 25/28
A61K 31/454
C07D 403/06
US Classification:

51425405, 546 20, 514278, 546211, 514326, 544371
Abstract:

Compounds of Formula (I), wherein R, R, R, R, R, R, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.